Literature DB >> 24091927

Light chain amyloidosis: the heart of the problem.

Giampaolo Merlini1, Giovanni Palladini.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24091927      PMCID： PMC3789451          DOI： 10.3324/haematol.2013.094482

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  28 in total

1.  Treatment with intravenous melphalan and dexamethasone is not able to overcome the poor prognosis of patients with newly diagnosed systemic light chain amyloidosis and severe cardiac involvement.

Authors:  Sascha Dietrich; Stefan O Schönland; Axel Benner; Tilmann Bochtler; Arnt V Kristen; Jörg Beimler; Ernst Hund; Markus Zorn; Hartmut Goldschmidt; Antony D Ho; Ute Hegenbart
Journal:  Blood       Date:  2010-04-07       Impact factor: 22.113

2.  CyBorD: stellar response rates in AL amyloidosis.

Authors:  Giampaolo Merlini
Journal:  Blood       Date:  2012-05-10       Impact factor: 22.113

Review 3.  Amyloidosis: pathogenesis and new therapeutic options.

Authors:  Giampaolo Merlini; David C Seldin; Morie A Gertz
Journal:  J Clin Oncol       Date:  2011-04-11       Impact factor: 44.544

4.  Human amyloidogenic light chain proteins result in cardiac dysfunction, cell death, and early mortality in zebrafish.

Authors:  Shikha Mishra; Jian Guan; Eva Plovie; David C Seldin; Lawreen H Connors; Giampaolo Merlini; Rodney H Falk; Calum A MacRae; Ronglih Liao
Journal:  Am J Physiol Heart Circ Physiol       Date:  2013-04-26       Impact factor: 4.733

5.  Infusion of light chains from patients with cardiac amyloidosis causes diastolic dysfunction in isolated mouse hearts.

Authors:  R Liao; M Jain; P Teller; L H Connors; S Ngoy; M Skinner; R H Falk; C S Apstein
Journal:  Circulation       Date:  2001-10-02       Impact factor: 29.690

6.  Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis.

Authors:  Giovanni Palladini; Carlo Campana; Catherine Klersy; Alessandra Balduini; Giovanbattista Vadacca; Vittorio Perfetti; Stefano Perlini; Laura Obici; Edoardo Ascari; Gianvico Melzi d'Eril; Remigio Moratti; Giampaolo Merlini
Journal:  Circulation       Date:  2003-04-28       Impact factor: 29.690

7.  Doxycycline reduces fibril formation in a transgenic mouse model of AL amyloidosis.

Authors:  Jennifer Ellis Ward; Ruiyi Ren; Gianluca Toraldo; Pam Soohoo; Jian Guan; Carl O'Hara; Ravi Jasuja; Vickery Trinkaus-Randall; Ronglih Liao; Lawreen H Connors; David C Seldin
Journal:  Blood       Date:  2011-10-12       Impact factor: 22.113

8.  Lenalidomide, melphalan and dexamethasone in a population of patients with immunoglobulin light chain amyloidosis with high rates of advanced cardiac involvement.

Authors:  Shira Dinner; Wesley Witteles; Anosheh Afghahi; Ronald Witteles; Sally Arai; Richard Lafayette; Stanley L Schrier; Michaela Liedtke
Journal:  Haematologica       Date:  2013-05-28       Impact factor: 9.941

9.  Left ventricular device implantation for advanced cardiac amyloidosis.

Authors:  Paul L Swiecicki; Brooks S Edwards; Sudhir S Kushwaha; Angela Dispenzieri; Soon J Park; Morie A Gertz
Journal:  J Heart Lung Transplant       Date:  2013-03-06       Impact factor: 10.247

10.  Stanniocalcin1 is a key mediator of amyloidogenic light chain induced cardiotoxicity.

Authors:  Jian Guan; Shikha Mishra; Jianru Shi; Eva Plovie; Yiling Qiu; Xin Cao; Davide Gianni; Bingbing Jiang; Federica Del Monte; Lawreen H Connors; David C Seldin; Francesca Lavatelli; Paola Rognoni; Giovanni Palladini; Giampaolo Merlini; Rodney H Falk; Marc J Semigran; G William Dec; Calum A Macrae; Ronglih Liao
Journal:  Basic Res Cardiol       Date:  2013-08-28       Impact factor: 17.165
View more
  28 in total

1.  Quantitative molecular imaging of cardiac amyloidosis: The journey has begun.

Authors:  Sharmila Dorbala; Marie Foley Kijewski; Mi-Ae Park
Journal:  J Nucl Cardiol       Date:  2015-07-16       Impact factor: 5.952

2.  Molecular imaging of misfolded protein pathology for early clues to involvement of the heart.

Authors:  Giampaolo Merlini; Jagat Narula; Eloisa Arbustini
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-07-03       Impact factor: 9.236

3.  Treating advanced cardiac damage in light chain amyloidosis: still an unmet need.

Authors:  Giampaolo Merlini; Giovanni Palladini
Journal:  Haematologica       Date:  2014-09       Impact factor: 9.941

Review 4.  AL amyloidosis: from molecular mechanisms to targeted therapies.

Authors:  Giampaolo Merlini
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

Review 5.  How to Image Cardiac Amyloidosis: A Practical Approach.

Authors:  Sharmila Dorbala; Sarah Cuddy; Rodney H Falk
Journal:  JACC Cardiovasc Imaging       Date:  2019-10-11

6.  Cardiac Light Chain Amyloidosis: The Role of Metal Ions in Oxidative Stress and Mitochondrial Damage.

Authors:  Luisa Diomede; Margherita Romeo; Paola Rognoni; Marten Beeg; Claudia Foray; Elena Ghibaudi; Giovanni Palladini; Robert A Cherny; Laura Verga; Gian Luca Capello; Vittorio Perfetti; Fabio Fiordaliso; Giampaolo Merlini; Mario Salmona
Journal:  Antioxid Redox Signal       Date:  2017-03-03       Impact factor: 8.401

7.  A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis.

Authors:  Vaishali Sanchorawala; Giovanni Palladini; Vishal Kukreti; Jeffrey A Zonder; Adam D Cohen; David C Seldin; Angela Dispenzieri; Arnaud Jaccard; Stefan O Schönland; Deborah Berg; Huyuan Yang; Neeraj Gupta; Ai-Min Hui; Raymond L Comenzo; Giampaolo Merlini
Journal:  Blood       Date:  2017-05-26       Impact factor: 22.113

Review 8.  Heart transplantation in cardiac amyloidosis.

Authors:  Matthew Sousa; Gregory Monohan; Navin Rajagopalan; Alla Grigorian; Maya Guglin
Journal:  Heart Fail Rev       Date:  2017-05       Impact factor: 4.214

9.  Melphalan and dexamethasone with or without bortezomib in newly diagnosed AL amyloidosis: a matched case-control study on 174 patients.

Authors:  G Palladini; P Milani; A Foli; M Vidus Rosin; M Basset; F Lavatelli; M Nuvolone; L Obici; S Perlini; G Merlini
Journal:  Leukemia       Date:  2014-07-25       Impact factor: 11.528

10.  Coagulation and fibrinolytic features in AL amyloidosis with abnormal bleeding and usefulness of tranexamic acid.

Authors:  Masahisa Arahata; Hiroyuki Takamatsu; Eriko Morishita; Yasuko Kadohira; Shinya Yamada; Akitada Ichinose; Hidesaku Asakura
Journal:  Int J Hematol       Date:  2020-01-03       Impact factor: 2.490
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.